Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept医疗向FDA提交了新药申请，以其专有的选择性皮质醇调节剂Relacorilant治疗库欣综合症患者。
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept医疗向FDA提交了新药申请，以其专有的选择性皮质醇调节剂Relacorilant治疗库欣综合症患者。
资讯热榜
更新时间